Hasan Sari1,2, Clemens Mingels3, Ian Alberts3, Jicun Hu4, Dorothee Buesser3, Vijay Shah4, Robin Schepers3, Patrik Caluori3, Vladimir Panin4, Maurizio Conti4, Ali Afshar-Oromieh3, Kuangyu Shi3, Lars Eriksson4,5, Axel Rominger3, Paul Cumming3,6. 1. Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, Switzerland. hasan.sari@siemens-healthineers.com. 2. Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland. hasan.sari@siemens-healthineers.com. 3. Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland. 4. Siemens Medical Solutions, USA Inc., Knoxville, TN, USA. 5. Department of Oncology and Pathology, Medical Radiation Physics, Karolinska Institutet, Stockholm, Sweden. 6. School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia.
Abstract
PURPOSE: To investigate the kinetics of 18F-fluorodeoxyglucose (18F-FDG) by positron emission tomography (PET) in multiple organs and test the feasibility of total-body parametric imaging using an image-derived input function (IDIF). METHODS: Twenty-four oncological patients underwent dynamic 18F-FDG scans lasting 65 min using a long axial FOV (LAFOV) PET/CT system. Time activity curves (TAC) were extracted from semi-automated segmentations of multiple organs, cerebral grey and white matter, and from vascular structures. The tissue and tumor lesion TACs were fitted using an irreversible two-tissue compartment (2TC) and a Patlak model. Parametric images were also generated using direct and indirect Patlak methods and their performances were evaluated. RESULTS: We report estimates of kinetic parameters and metabolic rate of glucose consumption (MRFDG) for different organs and tumor lesions. In some organs, there were significant differences between MRFDG values estimated using 2TC and Patlak models. No statistically significant difference was seen between MRFDG values estimated using 2TC and Patlak methods in tumor lesions (paired t-test, P = 0.65). Parametric imaging showed that net influx (Ki) images generated using direct and indirect Patlak methods had superior tumor-to-background ratio (TBR) to standard uptake value (SUV) images (3.1- and 3.0-fold mean increases in TBRmean, respectively). Influx images generated using the direct Patlak method had twofold higher contrast-to-noise ratio in tumor lesions compared to images generated using the indirect Patlak method. CONCLUSION: We performed pharmacokinetic modelling of multiple organs using linear and non-linear models using dynamic total-body 18F-FDG images. Although parametric images did not reveal more tumors than SUV images, the results confirmed that parametric imaging furnishes improved tumor contrast. We thus demonstrate the feasibility of total-body kinetic modelling and parametric imaging in basic research and oncological studies. LAFOV PET can enhance dynamic imaging capabilities by providing high sensitivity parametric images and allowing total-body pharmacokinetic analysis.
PURPOSE: To investigate the kinetics of 18F-fluorodeoxyglucose (18F-FDG) by positron emission tomography (PET) in multiple organs and test the feasibility of total-body parametric imaging using an image-derived input function (IDIF). METHODS: Twenty-four oncological patients underwent dynamic 18F-FDG scans lasting 65 min using a long axial FOV (LAFOV) PET/CT system. Time activity curves (TAC) were extracted from semi-automated segmentations of multiple organs, cerebral grey and white matter, and from vascular structures. The tissue and tumor lesion TACs were fitted using an irreversible two-tissue compartment (2TC) and a Patlak model. Parametric images were also generated using direct and indirect Patlak methods and their performances were evaluated. RESULTS: We report estimates of kinetic parameters and metabolic rate of glucose consumption (MRFDG) for different organs and tumor lesions. In some organs, there were significant differences between MRFDG values estimated using 2TC and Patlak models. No statistically significant difference was seen between MRFDG values estimated using 2TC and Patlak methods in tumor lesions (paired t-test, P = 0.65). Parametric imaging showed that net influx (Ki) images generated using direct and indirect Patlak methods had superior tumor-to-background ratio (TBR) to standard uptake value (SUV) images (3.1- and 3.0-fold mean increases in TBRmean, respectively). Influx images generated using the direct Patlak method had twofold higher contrast-to-noise ratio in tumor lesions compared to images generated using the indirect Patlak method. CONCLUSION: We performed pharmacokinetic modelling of multiple organs using linear and non-linear models using dynamic total-body 18F-FDG images. Although parametric images did not reveal more tumors than SUV images, the results confirmed that parametric imaging furnishes improved tumor contrast. We thus demonstrate the feasibility of total-body kinetic modelling and parametric imaging in basic research and oncological studies. LAFOV PET can enhance dynamic imaging capabilities by providing high sensitivity parametric images and allowing total-body pharmacokinetic analysis.
Authors: M Reivich; D Kuhl; A Wolf; J Greenberg; M Phelps; T Ido; V Casella; J Fowler; E Hoffman; A Alavi; P Som; L Sokoloff Journal: Circ Res Date: 1979-01 Impact factor: 17.367
Authors: K Schmidt; G Lucignani; R M Moresco; G Rizzo; M C Gilardi; C Messa; F Colombo; F Fazio; L Sokoloff Journal: J Cereb Blood Flow Metab Date: 1992-09 Impact factor: 6.200
Authors: Ole L Munk; Lars C Gormsen; André H Dias; Mette F Pedersen; Helle Danielsen Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-07 Impact factor: 9.236
Authors: Nicolas A Karakatsanis; Michael E Casey; Martin A Lodge; Arman Rahmim; Habib Zaidi Journal: Phys Med Biol Date: 2016-07-06 Impact factor: 3.609
Authors: Hasan Sari; Mohammadreza Teimoorisichani; Clemens Mingels; Ian Alberts; Vladimir Panin; Deepak Bharkhada; Song Xue; George Prenosil; Kuangyu Shi; Maurizio Conti; Axel Rominger Journal: Eur J Nucl Med Mol Imaging Date: 2022-07-19 Impact factor: 10.057